We herein propose the usage of a novel bioconjugation methodology to exploit antibody analogues (Ab) as delivery vehicles for oligonucleotide therapeutics (ON) to overcome current limits regarding ON specificity and potency. Novel therapeutically relevant Ab-ON conjugates will be synthesised, characterised, and biologically evaluated which potentially leads to a novel platform technology, which could be applied to other ONs.